GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B‐CELL LYMPHOMA (LBCL): EXTENDED FOLLOW‐UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY.

Authors :: Dickinson, M.
Carlo‐Stella, C.
Morschhauser, F.
Falchi, L.
Bachy, E.
Cartron, G.
Khan, C.
Tani, M.
Martinez‐Lopez, J.
Bartlett, N.
Salar, A.
Brody, J.
Leppä, S.
Mulvihill, E.
Lundberg, L.
Relf, J.
Xie, Y.
Bottos, A.
Humphrey, K.
Hutchings, M.
Source :: Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p144-146, 3p
Publication Year :: 2023
Abstract: B Introduction: b Glofitamab is a CD20xCD3 bispecific antibody delivered in a fixed course of 12 three-weekly cycles. GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): EXTENDED FOLLOW-UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY. [Extracted from the article]

Full Text Access

Tools